Replies to post #109575 on Biotech Values

[DewDiligence]

Will PYMX's PMX-60056 be tested for future use reversing Rivaroxaban and Dabigatran?

Rivaroxaban and dabigatran—and the other new oral anticoagulants—cannot be reversed by any known antidote.

An important part of the rationale for the M118 program in ACS is that M118 can be reversed by promatine (#msg-39146357).

[DewDiligence]

Portola will present additional preclinical data for FXa antidote at ESC:

http://finance.yahoo.com/news/Portola-Pharmaceuticals-iw-4201779648.html?x=0&.v=1

Today’s PR contends that PRT064445 can reverse the effect of direct FXa inhibitors, a class that includes Xarelto and Eliquis (and Portola's own Betrixaban), but not Pradaxa.

[DewDiligence]

Portola starts phase-1 trial of FXa antidote, PRT4445:

http://finance.yahoo.com/news/portola-advances-prt4445-first-class-120000986.html

PRT4445 is a recombinant biologic designed to reverse the anticoagulant activity of oral and injectable Factor Xa inhibitors in patients suffering life-threatening bleeds or requiring urgent surgery. No agents are approved to specifically reverse the activity of oral Factor Xa inhibitors. Current strategies for mitigating serious bleeding in patients taking Factor Xa inhibitors include the administration of coagulation factors such as recombinant Factor VIIa or blood-derived prothombin complex concentrates [the latter can also be used for reversing warfarin—see #msg-75232197]…

PRT4445 is billed as a companion product to Betrixaban, Portola’s FXa inhibitor in phase-3 that was once partnered with MRK (#msg-70839287, #msg-61300408); however, PRT4445 presumably works with Xarelto and Eliquis too (but not Pradaxa).